Popular Stories
RADAR on Medicare Advantage
-
The Inflation Reduction Act (IRA)’s $2,000 Part D spending cap, which took effect Jan. 1, is projected to help more than 11 million Medicare beneficiaries save $7 billion on prescription drugs, according to a new report...
-
As Medicare Advantage insurers saw increasing levels of utilization that coincided with shrinking reimbursement from CMS in 2024, this year’s plan offerings presented a level of change that consumers...
HEALTH PLAN WEEKLY
-
The Cigna Group recently announced it is working to streamline its prior authorization (PA) processes. Experts tell AIS Health that while PA improvements are sorely needed, the move appears to mostly be aimed at...
-
While 2024 was an especially challenging year for health insurers, a major credit-rating firm is now predicting that 2025 and beyond may not be that much better. ...
Radar On Speciality Pharmacy
-
More than two-and-a-half years after it first brought a lawsuit against SaveOnSP, Johnson & Johnson has added two additional divisions of The Cigna Group to the case challenging its copay maximizer program....
-
As more and more innovative therapies launch in the U.S., payers will continue to explore a variety of tactics in their coverage of those drugs, including carveouts, outcomes-based arrangements...
RADAR ON DRUG BENEFITS
-
In one of its final days in office, Joe Biden’s administration announced the next 15 drugs selected for Medicare drug price negotiations. By June 1, 2025, CMS will submit the maximum fair price of each newly selected drug...
-
The popular blockbuster diabetes and weight loss drugs — Ozempic and Wegovy — are among the 15 drugs selected for the second round of Medicare drug price negotiations as part of the Inflation Reduction Act,...
About AIS Health
AIS Health is a publishing and information company that has served the health care industry for more than 30 years. Our mission is to provide our readers with an actionable understanding of the business of health care and pharmaceuticals. Our in-depth writing covers the companies, people, catalysts and trends that create the richly textured contours of the health care and drug industry. AIS Health maintains journalistic independence from our parent company, MMIT. We are committed to integrity in reporting and bringing transparency to health industry data.


The Latest
Complimentary Publications
Premium Categories
Premium Categories
Get an actionable understanding of the business of health care and pharmaceuticals
Sign up for publications to get unmatched business intelligence delivered to your inbox.